pTVG-AR

Phase 2Biologic

UUniversity of Wisconsin, Madison

pTVG-AR is one of 40 biologic programs targeting Castration-resistant Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Castration-Resistant Prostate CancerActive, not recruiting

Prostate CancerActive, not recruiting

Castration-Resistant Prostate CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Cabometyx

Bristol-Myers Squibb

Phase 3

12 3

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

10 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 5

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

4 6

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 7

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Phase 3

4 8

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

pTVG-AR

UUniversity of Wisconsin, Madison

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Castration-Resistant Prostate Cancer

NCT04090528

Q4 2028

PreclinicalActive, not recruiting

Prostate Cancer

NCT04989946

Clinical

Trials by Indication[1]

Vaccine1 trial

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT02411786·40 enrolled

Castration-resistant Prostate Cancer1 trial

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT04090528·60 enrolled

Prostate Cancer1 trial

Phase I/II Trial of Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Active, not recruiting·UUniversity of Wisconsin, Madison·Preclinical·NCT04989946·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for pTVG-AR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pTVG-AR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pTVG-AR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Wisconsin, Madison company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Wisconsin, Madison

pTVG-AR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Trials by Indication[1]

Vaccine1 trial

Castration-resistant Prostate Cancer1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News